HUTCHMED (NASDAQ:HCM) Posts Earnings Results

HUTCHMED (NASDAQ:HCM) announced its earnings results on Thursday. The company reported $0.01 EPS for the quarter, FiscalAI reports. The business had revenue of $135.42 million for the quarter.

HUTCHMED Trading Up 0.9%

Shares of HUTCHMED stock traded up $0.12 on Thursday, hitting $13.77. 7,773 shares of the company traded hands, compared to its average volume of 38,277. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05. The business has a 50-day simple moving average of $14.70 and a 200 day simple moving average of $15.00. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $19.50.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, HUTCHMED currently has a consensus rating of “Hold” and a consensus target price of $20.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. lifted its position in HUTCHMED by 131.5% in the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after buying an additional 4,378 shares during the last quarter. Ameriprise Financial Inc. increased its position in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in HUTCHMED by 12.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock worth $273,000 after buying an additional 1,873 shares in the last quarter. Bank of America Corp DE boosted its position in HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after purchasing an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after purchasing an additional 5,538 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.